We are live on ! Find out more
VP

venBio Partners Portfolio holdings

AUM $281M
1-Year Est. Return 261.03%
This Fund
S&P 500
This Quarter Est. Return
+3.75%
1 Year Est. Return
+261.03%
3 Year Est. Return
+648.19%
5 Year Est. Return
+623.84%
10 Year Est. Return
–
AUM
$57.2M
AUM Growth
-$39.8M
Cap. Flow
-$27.4M
Cap. Flow %
-47.87%
Top 10 Hldgs %
100%
Holding
4
New
–
Increased
–
Reduced
1
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
NBRV
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
+$619K

Sector Composition

Rank Sector Weight
1 Healthcare 44.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VYNE icon
1
VYNE Therapeutics
VYNE
$17.5M
$14.4M 25.18%
20,299
– –
VRNA
2
DELISTED
Verona Pharma
VRNA
$10.9M 19.15%
875,000
– –
NBRV
3
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
– –
-712
Closed -$619K

Similar funds

FFP
Freedom Financial Partners Oakdale, Minnesota $281M AUM 16.89% 1-Year Est. Return
BDA
Borer Denton & Associates Blue Bell, Pennsylvania $280M AUM 7.09% 1-Year Est. Return
PHC
Panoramic Hills Capital Road Town $280M AUM
OFCM
One Fin Capital Management San Francisco, California $280M AUM 49.87% 1-Year Est. Return
SA
SoundView Advisors Olympia, Washington $281M AUM 17.96% 1-Year Est. Return
ACC
Acorn Creek Capital Fort Collins, Colorado $280M AUM 19.97% 1-Year Est. Return
NRCM
Northern Right Capital Management Darien, Connecticut $281M AUM 56.22% 1-Year Est. Return
IP
Investment Partners New Philadelphia, Ohio $281M AUM 20.9% 1-Year Est. Return

venBio Partners's Q3 2018 Portfolio in Review

As of Q3 2018, venBio Partners held 4 positions worth $57.2M, down 41% from $96.9M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

venBio Partners withdrew a net $27.4M in Q3 2018, closing 1 position and reducing 1 holding. Its most notable exit was Nabriva Therapeutics plc Ordinary Shares Ireland, an estimated $619K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 44% of assets, up from 25% a quarter earlier.

  • venBio Partners fully exited Nabriva Therapeutics plc Ordinary Shares Ireland in Q3 2018, selling an estimated $619K.
  • venBio Partners's ten largest holdings make up 100% of its $57.2M portfolio in Q3 2018.
  • venBio Partners opened 0 new positions and closed 1 in Q3 2018.
  • venBio Partners's portfolio value fell 41% quarter-over-quarter to $57.2M.

Based on venBio Partners's 13F filing for Q3 2018, filed 14 Nov 2018.